PARP (Poly ADP-Ribose Polymerase) Inhibitor Market: Size, Share, Growth, Analysis, Key Players, Revenue, Growth | Valuates Reports

PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size
The global PARP (Poly ADP-Ribose Polymerase) Inhibitor revenue was US$ 4686.4 million in 2022 and is forecast to a readjusted size of US$ 8571.2 million by 2029 with a CAGR of 8.9% during the forecast period (2023-2029).

View sample report
https://reports.valuates.com/request/sample/QYRE-Auto-19N16014/Global_and_India_PARP_Poly_ADP_Ribose_Polymerase_Inhibitor_Market_Report_Forecast_2023_2029

and India PARP (Poly ADP-Ribose Polymerase) Inhibitor Market
PARP inhibitors are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP).
They are developed for multiple indications; the most important is the treatment of cancer. Several forms of cancer are more dependent on PARP than regular cells, making PARP an attractive target for cancer therapy. PARP inhibitors appear to improve progression-free survival in women with recurrent platinum-sensitive ovarian cancer, as evidenced mainly by olaparib added to conventional treatment.
In our report, we only study four approved PARPi (Lynparza, Zejula, Rubraca and Talzenna). One unit is one tablet or one capsule.
In India, the PARP (Poly ADP-Ribose Polymerase) Inhibitor revenue is expected to grow from US$ million in 2022 to US$ million by 2029, at a CAGR of % during the forecast period (2023-2029).
Global PARP (Poly ADP-Ribose Polymerase) Inhibitor key players include AstraZeneca, Tesaro, Merck & Co, etc. Global top three manufacturers hold a share about 90%.
North America is the largest market, with a share about 70%, followed by Europe and Emerging Country, both have a share about 25 percent.
In terms of product, Lynparza is the largest segment, with a share over 65%. And in terms of application, the largest application is Ovarian Cancer, followed by Breast Cancer.

Get regional report
https://reports.valuates.com/request/regional/QYRE-Auto-19N16014/Global_and_India_PARP_Poly_ADP_Ribose_Polymerase_Inhibitor_Market_Report_Forecast_2023_2029

Segment by Type
• Lynparza
• Zejula
• Rubraca
• Talzenna
• Other

Segment by Application
• Ovarian Cancer
• Breast Cancer
• Other

By Company

AstraZeneca, Tesaro, Merck & Co, Clovis Oncology, Pfizer, GSK, Zai Lab

View full report
https://reports.valuates.com/market-reports/QYRE-Auto-19N16014/global-and-india-parp-poly-adp-ribose-polymerase-inhibitor

Valuates,
4th Floor,
Balaraj's Arcade,
Whitefield Main road,
Bangalore 560066,

Valuates offers an extensive collection of market research reports that helps companies to take intelligent strategical decisions based on current and forecasted Market trends.

This release was published on openPR.